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Background: There is partial evidence that COPD is expressed differently in women than in 
men, namely on symptoms, pulmonary function, exacerbations, comorbidities or prognosis. 
There is a need to improve the characterization of COPD in females. 
Methods: We obtained and pooled data of 17 139 patients from 22 COPD cohorts and analysed 
the clinical differences by sex, establishing the relationship between these characteristics in 
women and the prognosis and severity of the disease. Comparisons were established with 
standard statistics and survival analysis, including crude and multivariate Cox-regression 
analysis. 
Results: Overall, 5,355 (31.2%) women were compared with men with COPD. Women were 
younger, had lower pack-years, greater FEV1%, lower BMI and a greater number of 
exacerbations (all p<0.05). On symptoms, women reported more dyspnea, equal cough but less 
expectoration (p < 0.001). There were no differences in the BODE index score in women (2.4) 
versus men (2.4) (p = 0.5), but the distribution of all BODE components was highly variable by 
sex within different thresholds of BODE. On prognosis, 5-year survival was higher in COPD 
females (86.9%) than in males (76.3%), p < 0.001, in all patients and within each of the specific 
comorbidities that we assessed. The crude and adjusted RR and 95% C.I. for death in males was 
1.82 (1.69-1.96) and 1.73 (1.50-2.00), respectively. 
Conclusions: COPD in women has some characteristic traits expressed differently than 
compared to men, mainly with more dyspnea and COPD exacerbations and less phlegm, among 
others, although long-term survival appears better in female COPD patients. 











 Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterized 
by chronic, progressive and mostly irreversible airflow limitation, associated with exposure to 
tobacco smoke, inhalation of occupational or environmental toxins or biomass combustion 
products1,2. COPD is a complex and heterogeneous disease associated with high morbidity and 
mortality. According to the latest update of the Global Burden of Disease Study, the prevalence 
of COPD in 2017 was 174 million people worldwide3 and it was estimated that it became the 
third most common cause of death globally since 2012, after ischemic heart disease and 
cerebrovascular disease4. 
 Population aging, a phenomenon more seen in women due to their longer longevity than 
men, and massive female uptake of smoking, has led to an increase in respiratory diseases 
associated with smoking in women, especially in the middle-aged, which has increased not only 
the prevalence, but also the associated morbidity and mortality. In the USA, COPD is already 
the leading cause of death among female smokers5. Since 2000, the number of women dying 
from COPD in the USA surpassed the number of men6, and an assessment of mortality rates due 
to COPD showed a smaller decrease in the mortality rate among women with moderate or 
severe COPD than among men7.  
 Despite this evidence, COPD is still considered mainly a “men's disease” by some 
clinicians, associated with a diagnostic bias that contributes to under-diagnosis in women8. Two 
similar studies, one conducted in the USA and Canada,9 nd the other in Spain10, concluded that 
diagnosis of COPD was biased according to the sex of the patient. The results showed that given 
equivalent clinical conditions, men have a 1.5-fold chance of receiving a provisional diagnosis 
of COPD, a bias that is significantly reduced when abnormal spirometry results are available. 
Spirometry testing and referral to a pulmonologist are less common for women,11 who suffer a 








a consultation, or in some patients by the prevalence of symptoms of fatigue or depression that 
point to a different type of treatment.  
 
 Although data are limited, some studies have suggested that COPD is expressed 
differently in women than in men in relation to symptoms, pulmonary function, exacerbations or 
comorbidities12,13,14,15 such that there is a need to improve the characterization of the disease in 
females in order to optimize the therapeutic approach of these patients. To address this issue, we 
obtained and pooled data of 17 139 patients from 22 COPD cohorts from seven countries and 
analysed the clinical differences of COPD by sex, establishing the relationship between these 




 In this international study, we analysed patients from the COPD Cohorts Collaborative 
International Assessment (3CIA) initiative16. We obtained individual pooled data from 22 
prospective cohort studies that systematically recruited patients with COPD in publicy-funded 
hospitals, except for the Copenhagen City Heart Study (CCHS)17 and the HUNT study18, which 
were population-bases studies. Details of each individual study have been published previously. 
All patients had a definition of COPD characterized by a post-bronchodilator ratio between the 
forced expiratory volume in the first second (FEV1) and the forced vital capacity (FVC) of less 
than 0.7. Spirometry was performed using the standards provided by the American Thoracic 
Society and European Respiratory Society19.  We obtained a minimum individual dataset 
including the vital status (up to death, right truncation or 2017), age, sex, smoking status, pre-
bronchodilator and post-bronchodilator FEV1 and FVC, and dyspnea measured with the 








participating 3CIA cohorts provided individual patient data for pooled analysis. All participants 
provided informed written consent, and each study was approved by the respective ethics 
committee. 
 We evaluated the study sample using prognostic parameters for COPD patients: age, 
dyspnea by mMRC scale, exercise capacity by the 6-min walk distance (6MWD), health-related 
quality of life by the Saint George’s Respiratory Questionnaire (SGRQ) and BODE index 
score21. We also evaluated the presence of comorbidities by the Charlson index. Metabolic 
syndrome was defined as a cluster of three conditions: arterial hypertension, diabetes mellitus 
and obesity (BMI ≥ 30 kg/m2). Participants were classified using the GOLD 2019 spirometric 
system into four grades (1-4) based on post-bronchodilator percent predicted FEV1 as stage 1 
(FEV1≥ 80%), stage 2 (FEV1 79%-50%), stage 3 (FEV1 30%-49%) and stage 4 (FEV1 < 30%). 
Groups ABCD were defined by self-reported severity of dyspnea (mMRC) and severe 
exacerbations in the previous year1. 
 3CIA was an observational study with variable follow-up. For the present analysis, 
follow up was censored five years after recruitment. During this follow up period, the principal 
investigators of each centre reported patient medical records, hospital admissions and deaths in 
a prospective manner. 
Outcomes 
 The primary outcome was to better describe the clinical characteristics of women 
with COPD in a large international cohort of patients, evaluating the possible differential 
aspects of COPD versus men. Secondary outcomes were to analyse the mortality by all causes 
according to sex, as well as to evaluate the potential role of gender, among other variables, as a 










                The 3CIA database manager quality-controlled all data centrally and created a clean 
database with a data dictionary. All implausible or missing variables were queried with the 
original study investigators and removed the datum from the central database if errors could not 
be corrected. Because cohorts had different follow-up times, patients were censored at five 
years of follow-up. 
            Descriptive statistics used mean and standard deviation for continuous variables and 
counts with percentages for categorical variables. Comparisons between groups were performed 
with the chi-squared test for categorical variables and the ANOVA test for continuous variables. 
We estimated 5-year all-cause mortality by sex (total and by covariates), using Kaplan-Meier 
survival curves. We conducted both univariate and multivariate survival analyses based on the 
Cox proportional hazards model, using each of the potential predictors of mortality as 
independent variables and survival as the dependent variable. As per standard statistical 
practice, for the multivariate analysis, we only incorporated those variables significantly 
associated with mortality in the univariate analysis. Results were expressed as risk ratio (RR) 
with 95% confidence interval (CI). Alpha error was set at 0.05.  
 
RESULTS 
We pooled data from 22 COPD cohorts with a total of 17 139 patients. Table 1 shows 
demographic and clinical characteristics of patients by sex. Overall, 5,355 (31.2%) were women 
with a mean ± SD age of 62.1±10.1 years, significantly younger than men (65.0±10.2, p < 
0.001).  Women had lower pack-years (33.3 vs 47.8, p < 0.001), greater FEV1 (% predicted) 
(60.9% vs 56.2%, p < 0.001), lower body mass index (BMI; 26.4 vs 27.0, p < 0.001), and a 
greater number of exacerbations in the last year (1.2 vs 1.0, p = 0.008). Regarding symptoms, 
women reported higher grades of dyspnea by the mMRC scale (1.8 vs 1.7, p = 0.002), equal 
cough (p=0.407) but less expectoration (37.2% vs 45.9%, p < 0.001). Distribution of patients 








in the BODE index score in women versus men (2.4 in both groups, p = 0.5). Selected co-
morbidities, such as arterial hypertension and cardiovascular disease, quality of life (SGRQ) and 
some respiratory medications (LAMA or LABA or LABA + ICS), were also similar between 
sexes, all with p>0.05 (Table 1).  
We then compared clinical and physiologic characteristics between women and men 
stratified by degree of airflow obstruction (FEV1, % of predicted) (Table 2). Women with severe 
or very severe airflow limitation (< 50% FEV1 of predicted) were significantly younger, less 
smokers and had lower BMI than men, all with p < 0.001. They also reported higher grades of 
dyspnea and had more co-morbidities evaluated by the Charlson index (2.6 vs 2.3, p = 0.003). 
No gender differences were found in the number of exacerbations in the last year in these 
patients. Similarly, in the subgroup of patients with more preserved pulmonary function (FEV1 
≥ 50%), women also were younger, less smokers and presented a higher degree of dyspnea and 
worse nutritional status (BMI) than men; however, these women had less co-morbidities 
evaluated by the Charlson index (1.7 vs 2.4, p<0.001), a trend which was opposite to women 
with severe and very severe airflow limitation.  
Figure 1 shows the relationship between BODE index score and its components [BMI, 
FEV1 (% predicted), dyspnea (mMRC), 6MWD] by gender. Sex specific differences occurred in 
BMI at low BODE scores, MRC dyspnoea score in mid-range BODE scores (2-4), 6MWT 
distance at BODE scores ≤5 and FEV1 at BODE scores ≤6. 
Figure 2 shows Kaplan-Meier curves for 5-year mortality (all-cause mortality) by sex 
and selected co-morbidities (asthma, arterial hypertension, diabetes mellitus, cardiovascular 
disease and metabolic syndrome). The Kaplan-Meier analysis showed that survival was 
significantly higher in females (86.9%) than in males (76.3%), p < 0.001. Survival remained 
better for women even when stratified by co-morbidities (asthma; 88.6% vs 83.1%, p < 0.001; 
cardiovascular comorbidities (hypertension, diabetes, cardiovascular disease or metabolic 








Finally, Table 3 presents the crude relative risks of determinants of mortality, and a 
multivariate model with an adjusted analysis. As expected COPD mortality in COPD was 
increased in male, current-smokers, and was increased with mMRC, number of exacerbations, 
Charlson index and presence of all co-morbidities explored, except for asthma. In contrast, 
COPD mortality in COPD had a significantly inverse association with BMI, % predicted FEV1, 
and BMI. The most parsimonious multivariate model included sex, age and the single BODE 
components; as it can be seen, male sex was associated with increased mortality 1.73 (1.50-
2.00) after adjustment. 
 
DISCUSSION 
Within this large, international study that includes a significant representation of women 
(31.2% of patients enrolled), we report that women with COPD develop a disease with a 
number of specific clinical characteristics, and better survival. Also, differences by sex occur in 
all four BODE components, especially in less severe COPD. 
Several studies have previously reported sex-related differences in clinical 
manifestations of COPD, although our study has been carried out in a larger international cohort 
which brings both unprecedented precision and representativeness. Our results, aligned with 
previous publications8,12,14,22, confirm that women with COPD were younger and require less 
cumulative smoking exposure than men. They presented a more symptomatic disease in terms 
of dyspnea, although they reported less sputum than males, with no differences in cough, as 
reported elsewhere23. Regarding co-morbidities, the concomitant diagnosis of asthma in women 
(25.8%) was more frequent than in men (19.5%) p<0.001. However, unlike the data obtained in 
the analysis of other cohorts, diabetes mellitus was more frequent in men, without significant 
differences in arterial hypertension or cardiovascular disease14,24.  
In terms of functional impairment, we saw that women had greater FEV1 % than men. 








intensity of dyspnea (mMRC). Generally, for the same degree of airflow obstruction they were 
younger, less frequently current smokers, had lower BMI and higher dyspnea. Some studies 
suggest that other non-physiological factors, such as anxiety or depression, may be involved in 
the perception of dyspnea and should be systematically evaluated in female COPD patients25.  
In our study, we analysed the relationship between BODE index score and its 
components by sex. We found that women had better lung function (FEV1%) than men with the 
same BODE score, as long as this score was not higher than 6 points (no sex-related differences 
in very severe patients). With regard to exercise capacity, on the other hand, women had lower 
6MWD than men, except in patients with BODE score higher than 5 points (also very severe 
patients). In the case of nutritional status, women had lower BMI than men with the same 
BODE score, only in those cases with mild disease (BODE score less than 2 points). This 
evidence indicates that the differences by sex in either the contribution of each component of 
the BODE or in the total index score decrease as the severity of the disease increases, which is a 
novel finding. Since % predicted FEV1, dyspnea score and exercise capacity each provide 
independent information regarding severity in patients with COPD, the multi-dimensional 
BODE index might have greater prognostic value in women with COPD than men26. Our data 
suggested that the proportional weight of each of the components of the BODE index varied by 
sex, dyspnea by the mMRC scale and BMI being the most important parameters in women27.  
In terms of survival, population-based studies show that universally females live longer 
than males, but COPD epidemiological studies suggest that mortality rates are declining faster 
in men than in women with COPD7,28. Indeed there are few clinical studies that determined sex-
related differences in COPD survival, with contradictory results. Most of them included patients 
with severe disease and chronic respiratory failure29,30,31,32, except for one based on a well 
phenotyped population with a wide range of COPD severity; this study showed that all-cause 








Our study results support a better survival of women with COPD compared to men 
(crudely and adjusted by demographic and clinical factors). Males were older, had greater 
smoking exposure and a higher Charlson index score than females, so all these factors could 
contribute to the sex differences in the mortality of these patients. In terms of prognosis, the 
study shows that, adjusted for all the significant prognostic variables, male sex remained an 
independent adverse prognostic factor. In fact, men had an adjusted all-cause mortality risk 1.73 
times greater than women. Age and all four components of the BODE index also had an 
independent, deleterious effect on survival. Notably, the inverse association of BMI with 
mortality, both in the crude 0.98 (0.97-0.99), as well as the adjusted analyses 0.96 (0.95-0.97), 
further supports the so-called obesity paradox in COPD33. 
Our study has several limitations. Firstly, most of the patients were from hospital-based 
cohorts, and therefore may not represent the COPD population at large. Specifically, our study 
population could be affected by a well-described gender- bias in the diagnosis of COPD, which 
implies that women may, to some extent, be underrepresented. However, we do not consider 
that this fact distorts our findings or reduces its validity because our study includes a significant 
representation of women in a large cohort of patients with strict diagnostic criteria, which might 
be considered a strength. Secondly, only selected comorbidities were explored, so frequent 
diseases in women with COPD as anxiety, depression or osteoporosis were not objectively 
evaluated. Thirdly, the survival analysis evaluated all-cause mortality, as regrettably specific 
information about different causes of death was not collected consistently in all cohorts and 
participants.  
To conclude, our results indicate that women with COPD were younger, less frequently 
smokers, and had better pulmonary function, but experienced more dyspnea and exacerbations. 
However, women with COPD had better survival than men. Our findings highlight the existence 
of significant sex-related differences in COPD risk and outcomes, supporting the importance of 
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Table 1. Demographic and clinical characteristics of COPD patients, by gender 
Characteristics Women    
5,355 (31.2%) 
Men    
11,784 (68.8%) 
p value 
Age (years) 62.1± 10.1 65.0 ± 10.2 < 0.001 
BMI (kg/m2) 26.4 ± 6.1 27.0 ± 5.0 < 0.001 
Pack-year index 33.3 ± 25.6 47.8 ± 28.7 < 0.001 
GOLD 2019 group   < 0.001 
A 34.9% 39.4% 
B 41.0% 37.2% 
C 5.6% 6% 
D 18.5% 17.4% 
GOLD spirometric staging   < 0.001 
1 20.0% 14.5% 
2 47.1% 44.1% 
3 23.3% 29.8% 
4 9.5% 11.6% 
Number of exacerbations in the last year 1.2 ± 1.7 1.0 ± 1.5 0.008 
Dyspnea mMRC (points) 1.8 ± 1.4 1.7 ± 1.3 0.002 
Cough 52.5% 50.8% 0.407 
Sputum 37.2% 45.9% < 0.001 
FEV1 (% of predicted) 60.9 ± 23.2 56.2 ± 21.9 < 0.001 
6MWD 363.8 ± 120.2 396.3 ± 127.1 < 0.001 
BODE index  2.4 ± 2.3 2.4 ± 2.1 0.503 
SGRQ   38.9 ± 22.5 38.0 ± 21.9 0.098 
Charlson index 2.1 ± 1.9 2.3 ± 2.0 < 0.001 
Arterial hypertension 43.1% 43.1% 0.991 
Diabetes mellitus 5.3% 11.2% < 0.001 
Cardiovascular disease 27.6% 29.9% 0.079 
Asthma 25.8% 19.5% < 0.001 








LAMA or  LABA  20.1% 20.0% 0.349 
LABA + LAMA  5.2% 7.7% 0.038 
LABA + ICS 30.7% 30.5% 0.122 
LABA+LAMA+ICS  44.0% 41.8% 0.014 
 
Data are expressed as mean ± SD or %. Abbreviations: BMI, body mass index; GOLD, global 
obstructive lung disease; mMRC, modified medical research council; FEV1, forced expiratory 
volume in the first second; 6MWD, 6-minute walk distance; BODE body mass index, degree of 
airway obstruction, dyspnea and exercise capacity by 6MWD; SGRQ, St. George’s Respiratory 
Questionnaire; LAMA, long acting muscarinic antagonist; LABA, long acting Beta 2 agonist; 
















































Table 2. Comparison of clinical and physiologic characteristics between women and men 

















Age (years) 61.6 ± 10.5 64 ± 10.5 <0.001 63.1 ± 9.3 66.5 ± 9.4 <0.001 
BMI (kg/m2),  
 
26.7 ± 5.9 27.4 ± 4.8 <0.001 25.6 ± 6.4 26.4 ± 5.3 <0.001 
Pack-years,  32 ± 25 45.3 ± 28.1 <0.001 35.4 ± 26.3 51.2 ± 29.2 <0.001 
Charlson index,  1.7 ± 1.8 2.4 ± 1.9 <0.001 2.6 ± 1.9 2.3 ± 2 0.003 
Number of 
exacerbations in 
the last year,  
1.1 ± 1.6 0.7 ± 1.3 <0.001 1.3 ± 1.8 1.3 ± 1.6 0.674 
Dyspnea mMRC 
(points), n (%) 
 
0-1  60.1% 65.2% <0.001 22.7% 27.3% <0.001 
 2-4 39.9% 34.8% 77.3% 72.7% 
 
Data are expressed as mean ± SD or %. Abbreviations: BMI, body mass index; mMRC, 
















Table 3. Crude and multivariate analysis of predictors of mortality 
 
 Crude RR and 95% C.I. Adjusted RR and 95% C.I. 
Sex, male 1.82 (1.69-1.96) 1.73 (1.50-2.00) 
Age 1.07 (1.06-1.08) 1.04 (1.03-1.05) 
Smoking status 
 - Current 





   
BMI 0.98 (0.97-0.99) 0.96 (0.95-0.97) 
% predicted FEV1 0.97 (0.96-0.98) 0.98 (0.97-0.99) 
mMRC 1.39 (1.36-1.42) 1.14 (1.08-1.21) 
6-MWD 0.99 (0.99-0.99) 0.98 (0.97-0.99) 
   
AECOPD 1.11 (1.07-1.14) - 
Charlson index 1.13 (1.10-1.15) - 
Hypertension 1.23 (1.041.46) - 
Diabetes 1.58 (1.35-1.86) - 
Cardiovascular Disease 1.32 (1.13-1.55) - 
Asthma 0.98 (0.88-1.09) - 
   
Note: For the multivariate analysis, we only incorporated those variables significantly 
associated with mortality in the univariate analysis.  
Abbreviations: BMI: body mass index; 6-MWD: 6-minute walk distance; % predicted FEV1: 
percent predicted forced expiratory volume in the first second; AECOPD: acute exacerbations 






























Note: Data points represents mean value and 95% confidence interval. Framed areas (*) include those data points that show significant differences by gender (p <0.05)








FEMALE 5076 4872 4556 4083 2359 1745
MALE 11145 10500 9632 8645 5973 4813
Patients at risk 
A
Patients at risk                                                                                                                      
FEMALE 574 557 529 513 382 366
MALE 835 806 759 721 578 542
Patients at risk
FEMALE 243 221 181 153 138 127
MALE 888 826 708 625 551 449
B C
Patients at risk 
FEMALE 105 96 83 78 51 49
MALE 484 454 402 356 268 226
D
FEMALE 474 461 434 402 97 92
MALE 1012 943 873 786 215 180
Patients at risk
FEMALE 1680 1595 1472 1302 709 521
MALE 4105 3878 3567 3179 2102 1680
Patients at risk
E F
Figure 2. Five-year survival curves of COPD patients by gender in A) all; B) Asthma; C) Hypertension; D) Diabetes; E) Cardiovascular 











- There are sex-related differences in COPD risk and outcomes. 
- Women with COPD are younger, less frequently smokers and had better lung 
function, but experienced more dyspnea and more exacerbations.  
- Our data suggest that the proportional weight of each of the components of the 
BODE index varied by sex.  
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